HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

Abstract

In predominantly lipoatrophic patients, switching from HIV protease inhibitor therapy lead to improved lipids and less intra-abdominal fat, but also to less peripheral fat, and had minimal effect on insulin resistance. Virological control in these heavily pretreated patients was unaffected, despite frequent switch drug cessations.